ATH — Alterity Therapeutics Share News
0.000.00%
Last trade - 00:00- AU$1.96m
- -AU$47.14m
- AU$0.45m
Brief: Alterity Therapeutics Posts HY Net Loss After Tax Attributable Of A$8.0 Million
Brief: Alterity Therapeutics Gets Authorization In France & Austria To Proceed With Phase 2 Clinical Trial
Alterity rises after lead drug prevents brain cell death in Parkinson’s animal model study
Brief: Alterity's ATH434 Prevents Loss Of Brain Cells In Parkinson's Disease Animal Model
Brief: Alterity Therapeutics Launches ATH434 Phase 2 Clinical Trial In Italy
Brief: Alterity Therapeutics Announces 1-For-10 Reverse ADS Split
Australia's Alterity Therapeutics leaps most in 3 mths on patent grant
Brief: Alterity Therapeutics Announces U.S. FDA Approval For IND Application For ATH434 For MSA
Alterity Therapeutics gains on FDA nod for rare Parkinson's disorder drug
Brief: Alterity Therapeutics Says FY Revenue For Ordinary Activities Down 87.9% To A$2,504
Alterity Therapeutics rises on launch of lead drug trial in UK
Brief: Alterity Therapeutics Says Regulatory Approval To Proceed With Phase 2 Trial In Italy
Brief: Alterity Reports Regulatory Authorization To Proceed With ATH434 Trial In United Kingdom
Australia's Alterity Therapeutics rise on grant of Phase 2 approval from UK Body
Brief: Alterity Therapeutics Says UK Regulatory Authorisation To Proceed With Phase 2 Trial Of ATH434
Australia Stock Exchange release from ALTERITY THERAPE : Change in substantial holding
Australia Stock Exchange release from ALTERITY THERAPE : Change in substantial holding
Australia Stock Exchange release from ALTERITY THERAPE : Alterity to participate in Sachs Neuroscience Conference
Australia Stock Exchange release from ALTERITY THERAPE : Investor Presentation